UCL Therapeutic Innovation Networks


Biologics Translation Roadmap

Where are you up to with your Biologics project? Use the icons below to learn about the steps needed for successful translation of biologics and what UCL support is available at each stage of the process.

UCL and partner NHS Trusts are globally leading innovators in the discovery, design, development, bioprocessing, formulation and clinical delivery of biologics including proteins, peptides, oligonucleotides and vaccines.

This roadmap provides a simplified workflow summarising key activities and considerations for development, evaluation and commercialisation of biologics, to facilitate their effective translation into the clinic. 

pathway icon

Therapeutic Design & Development

The Therapeutic Design & Development phase of Biologics translation should involve an understanding of the patients needs in order to identify opportunities for clinical benefit. Additional considerations include the Target Product Profile (TPP) and Intellectual Property (IP). 

pathway icon

Laboratory Evaluation

In the Laboratory Evaluation stage of Biologics translation, it is important to address the question: Does your research grade product match the Target Product Profile (TPP) and meet all the essential requirements?

pathway icon

Clinical Evaluation

Drug developers are required to conduct First-in-Man clinical trials to establish the safety of a new therapeutic in human subjects. Clinical evaluation must include Phase I and II clinical trials, and regulatory approvals. 

pathway icon

Commercial Adoption

The section includes manufacturers regulatory requirements for commercial adoption after completing the primary clinical safety and efficacy evaluation.